|
|
| No drug can be discovered, no medical condition diagnosed and no disease cured without researchers having access to proper biological specimens, relevant and accurate clinical data and state-of-the-art computational techniques. |
|
Our Mission
Leverage Health Discovery’s intellectual property and clinical partnerships as the world technology leader in biomarker discovery and the science of pharmacogenomics to develop drugs that promise maximum therapeutic benefits with minimal risks for each individual patient.
Our Vision
Our vision is to reshape the delivery of medicine in order to redefine the relationship between diagnostics, therapeutics and treatment by delivering personalized medicine that incorporates patient-specific information from gene expression, proteomics, metabolic indicators and therapeutic response.
Market Opportunity
The Food and Drug Administration (FDA), following its initiative in 1987 to expedite approval for new drugs, is encouraging biomarker discovery as key to early detection diagnostics and avoiding newdrug failures in late stage trials. In July 2004, Health Discovery bought the rights to use a patent portfolio of machine learning tools to identify key biomarkers in diagnostics and drug discovery. In May, the Company acquired complete control over the portfolio, comprising over 70 patents and giving Health Discovery ownership of additional patents that are the basis for initiating licensing arrangements and partnerships with numerous businesses unrelated to drug discovery.
|
|
Our team has identified and patent protected four major new discoveries.
1. A subset of genes that separates BPH from prostate cancer with a high degree of accuracy. This same set of genes also separates BPH from normal, indicating that BPH is a disease with molecular characteristics of its own.
2. An AIDS gene set that can separate AIDS brain cells from non-AIDS brain cells with a high degree of accuracy.
3. A subset of genes which indicate disease progression from less malignant to more malignant forms of prostate cancer. Such genes separate grade 4 prostate cancer, the most malignant form of prostate cancer, from less malignant grades of prostate cancer and normal tissues with a high degree of accuracy.
4. A set of leukemia genes that can separate ALL-T-cell leukemia from ALL-B-cell leukemia with a high degree of accuracy. |
|